Hilde furberg

Biography

 Ms. Hilde Furberg has served as Non-Executive Independent Director of BERGENBIO ASA since January 16, 2017. She was Chairman of the Board of the Company from February 2016 till January 16, 2017. Before that, she has been Non-Executive Director of the Company from June 22, 2015. Hilde Furberg has over 30 years of commercial experience in Pharma and Biotech, she is currently Senior Vice President Rare Diseases EMEA at Sanofi Genzyme. Previously her roles were Vice President and General Manager of Nordic Benelux and Nordic General Manager at Sanofi Genzyme. Prior to joining Genzyme, Ms. Furberg was Managing Director and part-owner of Pharmalink and held a number of roles at Baxter including Managing Director Sweden. She is currently Vice Chairman of the Board at Pharmalink AB and Board Member of J&J Future Invest AS, and has held board positions at Algeta ASA, Clavis Pharma ASA, Pronova Biopharma ASA and Probi.

Research Interest

 Pharmaceutical Science